Abstract 1877
Background
Based on mRNA expression, accRCC can be divided in four molecular subtypes (ccrcc1-4), associated with prognosis, angiogenic signature, immune phenotype and therapy response. miRNAs are master regulators of mRNA function. We assessed the correlation of miRNA expression with (1) ccrccc1-4 subtypes, (2) mRNA targets and (3) outcome.
Methods
We performed miRNome analysis of 128 accRCC. (1) Unsupervised hierarchical clustering was done using 50 miRNAs with the most variable expression across all samples. Results were validated on TCGA data (n = 255). (2) For miRNAs with subtype-specific expression, we performed pathway analysis of predicted mRNA targets (IPA, KEGG) and assessed target-downregulation in TCGA. (3) We used Cox regression to correlate miRNA expression with overall survival (OS) since diagnosis. Hazard ratios (HR) were correlated with subtype-specific expression (Pearson).
Results
(1) Samples separated in two miRNA clusters, that partially overlapped with molecular subtypes. Cluster 1 consisted of 69% favourable subtypes (ccrcc2 or 3), cluster 2 of 77% unfavourable (ccrcc1 or 4) (p < 2.2e-16). (2) Pathway analysis of predicted mRNA targets and targets suppressed in TCGA, suggested that favourable subtypes exhibit more angiogenic signaling, whereas unfavourable subtypes activate pathways involved in tumor invasiveness. (3) Several miRNAs were significantly associated with OS. There was a robust correlation in the entire dataset between HR for OS and differential expression between favourable/unfavourable subtypes (r = 0.322; p < 0.0001).Table:
973P
miRNA | Subtype-specific expression log2FoldChange <0: higher in ccrcc1 or -4 (unfavourable) log2FoldChange >0: higher in ccrcc2 or -3 (favourable) | *p<0.05 ** false discovery rate <0.05 | Overall survival (hazard ratio) | |
---|---|---|---|---|
182-5p | -1,43 | ** | 1,25 | ** |
3529-3p | -1,42 | ** | 1,37 | ** |
335-3p | -1,33 | ** | 1,25 | ** |
34c-5p | -1,22 | ** | 1,25 | ** |
193b-3p | -1,17 | ** | 1,31 | ** |
370-3p | -1,07 | ** | 1,16 | ** |
199b-5p | -1,05 | ** | 1,26 | ** |
21-3p | -0,89 | ** | 1,47 | ** |
574-5p | -0,89 | ** | 1,40 | ** |
4792 | -0,88 | ** | 0,88 | * |
let-7i-5p | -0,81 | ** | 1,66 | ** |
652-3p | -0,75 | ** | 1,39 | ** |
1301-3p | -0,70 | ** | 1,39 | ** |
222-3p | -0,66 | ** | 1,31 | * |
320a | -0,63 | ** | 1,28 | ** |
425-5p | -0,62 | ** | 1,66 | ** |
149-5p | -0,61 | ** | 1,32 | * |
146b-5p | -0,54 | * | 1,49 | ** |
193b-5p | -0,49 | 1,21 | ** | |
185-5p | -0,49 | ** | 1,42 | ** |
21-5p | -0,42 | * | 1,68 | ** |
7641 | -0,33 | 0,80 | ** | |
320b | -0,28 | 1,25 | ** | |
1260b | -0,15 | 0,79 | ** | |
4454 | 0,15 | 0,80 | ** | |
6880-5p | 0,25 | 0,64 | ** | |
27b-3p | 0,36 | ** | 0,71 | * |
1260a | 0,38 | 0,73 | ** | |
7977 | 0,39 | 0,73 | ** | |
23b-3p | 0,48 | ** | 0,81 | ** |
2392 | 0,55 | 0,80 | ** | |
194-5p | 0,55 | * | 0,74 | ** |
30c-5p | 0,70 | ** | 0,78 | * |
190a-5p | 0,86 | ** | 0,83 | ** |
204-5p | 1,23 | ** | 0,71 | ** |
135a-5p | 1,37 | ** | 0,86 | ** |
Conclusions
accRCC molecular subtypes exhibit different miRNA expression patterns. Differentially expressed miRNAs are implicated in pathways driving tumor biology and strongly correlated with OS. These findings underscore the robustness of the molecular subtypes and are, to the best of our knowledge, the first to show an association of global miRNome expression with outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fonds Wetenschappelijk Onderzoek Vlaanderen.
Disclosure
M. Albersen: Research grant / Funding (self): Ipsen. B. Beuselinck: Advisory / Consultancy, Research grant / Funding (self): Bristol Meyers Squibb; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract